Lucid Diagnostics Inc. (NASDAQ:LUCD – Free Report) – Research analysts at Cantor Fitzgerald dropped their FY2023 earnings per share (EPS) estimates for shares of Lucid Diagnostics in a research note issued to investors on Wednesday, November 15th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings of ($1.26) per share for the year, down from their prior forecast of ($1.14). Cantor Fitzgerald has a “Overweight” rating and a $4.00 price target on the stock. The consensus estimate for Lucid Diagnostics’ current full-year earnings is ($1.14) per share. Cantor Fitzgerald also issued estimates for Lucid Diagnostics’ FY2024 earnings at ($0.89) EPS.
Separately, Needham & Company LLC cut their price target on Lucid Diagnostics from $2.80 to $2.50 and set a “buy” rating for the company in a research note on Tuesday, November 14th.
Lucid Diagnostics Stock Performance
LUCD stock opened at $1.31 on Monday. The company has a market capitalization of $58.52 million, a P/E ratio of -1.01 and a beta of 1.81. Lucid Diagnostics has a 52-week low of $1.04 and a 52-week high of $2.12. The business has a 50-day simple moving average of $1.32 and a two-hundred day simple moving average of $1.43.
Hedge Funds Weigh In On Lucid Diagnostics
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Citadel Advisors LLC boosted its stake in shares of Lucid Diagnostics by 14.6% in the 3rd quarter. Citadel Advisors LLC now owns 35,333 shares of the company’s stock worth $54,000 after buying an additional 4,506 shares during the last quarter. BlackRock Inc. lifted its stake in Lucid Diagnostics by 39.5% in the second quarter. BlackRock Inc. now owns 26,304 shares of the company’s stock valued at $37,000 after purchasing an additional 7,448 shares during the last quarter. Verition Fund Management LLC lifted its stake in Lucid Diagnostics by 29.2% in the second quarter. Verition Fund Management LLC now owns 46,709 shares of the company’s stock valued at $106,000 after purchasing an additional 10,543 shares during the last quarter. State Street Corp lifted its stake in Lucid Diagnostics by 24.4% in the first quarter. State Street Corp now owns 56,693 shares of the company’s stock valued at $190,000 after purchasing an additional 11,121 shares during the last quarter. Finally, LPL Financial LLC lifted its stake in Lucid Diagnostics by 97.2% in the third quarter. LPL Financial LLC now owns 28,400 shares of the company’s stock valued at $33,000 after purchasing an additional 14,000 shares during the last quarter. Hedge funds and other institutional investors own 4.30% of the company’s stock.
Lucid Diagnostics Company Profile
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test.
- Five stocks we like better than Lucid Diagnostics
- How to Calculate Stock Profit
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- How to Invest in Insurance Companies: A Guide
- MarketBeat Week in Review – 11/13 – 11/17
- What Are Utility Stocks? An Overview of the Utilities Sector
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.